As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance
Blockbuster Potential In Late-Stage Pipeline
Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.
